| Pharmaceutical Information |
| Drug Name |
Metyrapone |
| Drug ID |
BADD_D01450 |
| Description |
An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome. |
| Indications and Usage |
Used as a diagnostic drug for testing hypothalamic-pituitary ACTH function. Occasionally used in Cushing's syndrome. |
| Marketing Status |
approved; investigational |
| ATC Code |
V04CD01 |
| DrugBank ID |
DB01011
|
| KEGG ID |
D00410
|
| MeSH ID |
D008797
|
| PubChem ID |
4174
|
| TTD Drug ID |
D0Q9JT
|
| NDC Product Code |
70219-0001; 55361-0011; 76336-455 |
| UNII |
ZS9KD92H6V
|
| Synonyms |
Metyrapone | Methbipyranone | Methopyrapone | SU 4885 | Metopirone | Métopirone | Metopiron |
|
| Chemical Information |
| Molecular Formula |
C14H14N2O |
| CAS Registry Number |
54-36-4 |
| SMILES |
CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
